The prophylaxis of fungal infections.
With the increase in use of immunosuppressive therapies, solid organ and bone marrow transplantation and the recognition of the acquired immune deficiency syndrome (AIDS) an increased incidence and awareness of fungal infection has occurred in almost all disciplines of medicine. The problem of being unable to identify such infections accurately before serious morbidity or mortality occurs indicates a continued need for a prophylactic approach to these infections. Fortunately, the development of new, safer antifungal agents appears to be occurring. Novel approaches with amphotericin B and the use of bone marrow growth factors merit attention. Specific recommendations for antifungal prophylaxis depend on a number of factors pertinent to the individual treatment centre.
Powles
R L
RL
Leukaemia Unit, Royal Marsden Hospital, Sutton, Surrey, UK.
Milliken
S
S
D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use; D006801:Humans; D009181:Mycoses / Q000517:prevention & control*; D012306:Risk
D000935:Antifungal Agents